Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 20, 2026

ASX Stocks Estimated To Be Undervalued By Up To 30.4%

View original at finance.yahoo.com
ASX Stocks Estimated To Be Undervalued By Up To 30.4% As the Australian market faces a cautious opening with expectations of a 20-point drop, driven by concerns over rising U.S…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Integral Diagnostics (ASX:IDX) is estimated to be undervalued by 48.3% based on cash flows, with current price A$2.04 vs fair value estimate A$3.95

    60% confidence
  • Acrow (ASX:ACF) is estimated to be undervalued by 44.5% based on cash flows, with current price A$0.785 vs fair value estimate A$1.42

    60% confidence
  • ALS is poised for substantial financial growth

    60% confidence
  • ALS Limited's current trading price of A$23.15 is approximately 10.8% below its estimated future cash flow value of A$25.96, suggesting potential undervaluation based on cash flows

    60% confidence
  • Despite a high level of debt, ALS is actively seeking acquisitions that align with its strategic goals and return hurdles, potentially enhancing shareholder value further

    60% confidence
  • Rising U.S. bond yields are driving concerns over potential price pressures in the Australian economy

    60% confidence
  • Symal Group (ASX:SYL) is estimated to be undervalued by 48.8% based on cash flows, with current price A$2.46 vs fair value estimate A$4.80

    60% confidence
  • ALS reported strong earnings growth of 24.4% over the past year

    60% confidence
  • NRW Holdings (ASX:NWH) is estimated to be undervalued by 45.4% based on cash flows, with current price A$7.06 vs fair value estimate A$12.93

    60% confidence
  • Judo Capital Holdings (ASX:JDO) is estimated to be undervalued by 47.6% based on cash flows, with current price A$1.315 vs fair value estimate A$2.51

    60% confidence
  • Light & Wonder (ASX:LNW) is estimated to be undervalued by 40.8% based on cash flows, with current price A$113.85 vs fair value estimate A$192.44

    60% confidence
  • ReadyTech Holdings (ASX:RDY) is estimated to be undervalued by 45.3% based on cash flows, with current price A$1.365 vs fair value estimate A$2.49

    60% confidence
  • Nuix (ASX:NXL) is estimated to be undervalued by 49.6% based on cash flows, with current price A$1.295 vs fair value estimate A$2.57

    60% confidence
  • SiteMinder (ASX:SDR) is estimated to be undervalued by 49.3% based on cash flows, with current price A$2.66 vs fair value estimate A$5.25

    60% confidence
  • Elsight (ASX:ELS) is estimated to be undervalued by 48.4% based on cash flows, with current price A$5.74 vs fair value estimate A$11.13

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com